Nomogram of critical probability model in HFRS patients.

Nomogram of critical probability model in HFRS patients.

<p>Nomogram of critical probability model in HFRS patients.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Longjiao Dou (22319777) (author)
مؤلفون آخرون:	Yanxia Huang (4428490) (author), Haizhou Miao (22319780) (author), Songchang Xiu (22319783) (author), Fengmin Hu (22319786) (author), Hongyi Chen (2097328) (author), Daya Luo (20605656) (author), Shumei Wang (167633) (author)
منشور في:	2025
الموضوعات:	Medicine Biotechnology Immunology Developmental Biology Cancer Science Policy Infectious Diseases Virology Biological Sciences not elsewhere classified timely clinical intervention significant clinical utility patient &# 8217 multivariate analysis revealed comparable net benefit collected clinical data calibration plots indicated traditional coagulation tests good predictive ability blood coagulation objectively xlink "> thromboelostograms external validation auc critically ill patients criticality model equation combined thromboelastography test 50 &# 8211 00 &# 8211 noncritical groups according critical group 40 gof p value xlink "> noncritical group predictive value coagulation status coagulation indices noncritical patients critical group validated internally two groups thromboelastography indices single parameter significantly different renal syndrome prognostic factor patients died median duration median age male patients lower levels large proportion laboratory parameters january 2021 january 2017 independently associated higher levels head start haemorrhagic fever ethics committee early stages early predictor
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Clinical features of HFRS patients in the training cohort.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Logistic regression analysis of critical condition in patients with HFRS.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Predictive value of laboratory parameters for prognosis (critical severity) in HFRS patients.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Grouping criteria based on the HFRS<sup>a</sup> clinical classification criteria.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Comparison of laboratory parameters of first medical contacts in a training cohort of HFRS patients.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Internal and external validation of models.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Validation cohort.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Training cohort.
حسب: Longjiao Dou (22319777)
منشور في: (2025)

Association of EGb drug interactions with bleeding and abnormal coagulation tests (n = 747).
حسب: Ngo Thi Quynh Mai (20877011)
منشور في: (2025)

Clinical characteristics and drug interactions of the patient group to evaluate the relationship between DDI of EGb - bleeding/coagulopathy (n = 747).
حسب: Ngo Thi Quynh Mai (20877011)
منشور في: (2025)

Interaction between EGb and conventional drugs (n = 2,647).
حسب: Ngo Thi Quynh Mai (20877011)
منشور في: (2025)

Study diagram.
حسب: Ngo Thi Quynh Mai (20877011)
منشور في: (2025)

Data_ddi.
حسب: Ngo Thi Quynh Mai (20877011)
منشور في: (2025)

Correlations of selected inflammatory markers with results of coagulation tests.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlations of selected inflammatory markers to other anthropological and biochemical parameters.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlations of selected biochemical profiles with the coagulation values.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Parameters comparison between the healthy and type 1 diabetes mellitus (DMT1) group.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Differences in prothrombin time (PT) based on the body mass index (BMI) range in healthy donors and DMT1 patients after treatment with anticoagulants.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Differences in activated partial thromboplastin time (aPTT) based on the age ranges in healthy donors and DMT1 patients after treatment with anticoagulants.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Differences in prothrombin time (PT) based on the age ranges in healthy donors and DMT1 patients after treatment with anticoagulants.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Coagulation differences between healthy donors and DMT1 patients.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Impact of lactate (A-C) and hyperosmolarity (20 mM sodium chloride, D-F) treatment.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Impact of short-term (3 minutes, A-C) and long-term (60 minutes, D-F) treatment with glucose.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlation between activated partial thromboplastin time (aPTT) and vitamin K<sub>2</sub> form MK-4.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlation between prothrombin time (PT, expressed as INR: international normalized ratio) and vitamin K<sub>1</sub> (A) and (B) vitamin K<sub>2</sub> form MK-4.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlations of the effect of tested anticoagulants (reported as INR or aPTT) with HbA1C in type 1 diabetes mellitus patients.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Comparison of glycated hemoglobin in relation to age (A), sex (B), BMI (C), and smoking habit (D) in type 1 diabetes mellitus patients.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlation between activated partial thromboplastin time (aPTT) and selected biochemical parameters.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Correlation among prothrombin time (PT, expressed as INR: international normalized ratio) and selected biochemical parameters.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Comparison of (A) prothrombin time (PT, expressed as INR: international normalized ratio) and (B) activated partial thromboplastin time (aPTT) values for the negative control (solvent DMSO) and tested anticoagulants in relation to the levels of glycated haemoglobin in recruited type 1 diabetes mellitus patients.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Comparison of (A) prothrombin time (PT, expressed as INR: international normalized ratio) and (B) activated partial thromboplastin time (aPTT) values for the negative control (solvent DMSO) and all tested anticoagulants based on the fasting levels of glucose.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Differences in activated partial thromboplastin time (aPTT) based on the BMI ranges in healthy donors and DMT1 patients after treatment with anticoagulants.
حسب: Alejandro Carazo (2737303)
منشور في: (2025)

Coagulation profile abnormalities among hypertensive patient participants at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Northwest Ethiopia, 2023, (n = 120).
حسب: Mitku Kassa (22041517)
منشور في: (2025)

Comparison of platelet count and coagulation profiles of study participants at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Northwest Ethiopia, 2023, (n = 180).
حسب: Mitku Kassa (22041517)
منشور في: (2025)

Socio-demographic, clinical characteristics and anthropometric measurements of the study participants at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Northwest Ethiopia, 2023, (n = 180).
حسب: Mitku Kassa (22041517)
منشور في: (2025)

Raw data (HTN + control anonymized data set).
حسب: Mitku Kassa (22041517)
منشور في: (2025)

The predictive values of INR, DBP SD, and their combination for outcome.
حسب: Lijun Jiang (288611)
منشور في: (2025)

Logistic regression analysis of directly correlated factors for outcome.
حسب: Lijun Jiang (288611)
منشور في: (2025)

Comparison of BPV between the good and the poor outcome group, mean±SD.
حسب: Lijun Jiang (288611)
منشور في: (2025)

Comparison of coagulation function between the good and the poor outcome group, mean±SD/ median (IQR).
حسب: Lijun Jiang (288611)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_kpv5p17t7nhrglahu3918s8n51